Wall Street trims can­cer drug de­vel­op­er BioN­Tech's uni­corn val­u­a­tion

Mar­ket con­di­tions in the Unit­ed States are spook­ing in­vestors. Af­ter ADC Ther­a­peu­tics re­scind­ed its plans ear­li­er this month for a pub­lic list­ing — cit­ing an ad­verse en­vi­ron­ment — Ger­many’s BioN­Tech on Thurs­day un­veiled its down­sized IPO, rais­ing about $100 mil­lion less than the $251 mil­lion that it had pre­vi­ous­ly en­vi­sioned.

Found­ed in 2008, the can­cer drug de­vel­op­er ear­ly last month orig­i­nal­ly pen­ciled in plans for a $100 mil­lion US IPO. Then, lat­er in Sep­tem­ber, it broke out the num­bers: it was look­ing to of­fer 13.2 mil­lion Amer­i­can de­pos­i­to­ry shares (ADS) at a price range of $18 to $20 to raise $251 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER